Looking at the Big Picture for Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics, Inc. (NASDAQ:TENX) is one of the active stocks and its unusual movement is raising eyebrows among traders. Now trading with a market value of 13.95M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. In light of the many issues surrounding this company, we thought it was a good time to take a close look at the numbers in order to form a realistic perspective on the fundamental picture for this stock.

Tenax Therapeutics, Inc. (NASDAQ:TENX) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For TENX, the company currently has 2.23 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 13.45 million in total assets, balanced by 2.18 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Tenax Therapeutics, Inc. (TENX) saw -5.6 million in free cash flow last quarter, representing a quarterly net change in cash of -4.79 million. Perhaps most importantly where cash movements are concerned, the company saw about -5.6 million in net operating cash flow.

Tenax Therapeutics, Inc. (NASDAQ:TENX) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the TENX saw sales decline by 0.00.

But what about the bottom line? After all, that’s what really matters in the end. Tenax Therapeutics, Inc. (TENX) is intriguing when broken down to its core data. The cost of selling goods last quarter was 4,167, yielding a gross basic income of -4,167 . For shareholders, given the total diluted outstanding shares of 28.24 million, this means overall earnings per share of -0.11. Note, this compares with a consensus analyst forecast of -0.04 in earnings per share for its next fiscal quarterly report.

Is Tenax Therapeutics, Inc. (NASDAQ:TENX) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.31 in total earnings per share. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Tenax Therapeutics, Inc..

Previous ArticleNext Article

Related Post

Should You Buy Altaba Inc. (AABA) or U.S. Global I... Altaba Inc. (NASDAQ:AABA) shares are up more than 81.17% this year and recently decreased -0.43% or -$0.3 to settle at $70.06. U.S. Global Investors, ...
Financially Devastating or Fantastic? – Abra... The shares of Abraxas Petroleum Corporation have increased by more than 13.41% this year alone. The shares recently went up by 2.95% or $0.08 and now ...
ConocoPhillips (COP) vs. Noble Energy, Inc. (NBL):... ConocoPhillips (NYSE:COP) shares are down more than -0.02% this year and recently increased 1.97% or $0.97 to settle at $50.13. Noble Energy, Inc. (NY...
Financial Metrics You Should Care About: TrovaGene... The shares of TrovaGene, Inc. have decreased by more than -13.11% this year alone. The shares recently went down by -3.82% or -$0.01 and now trades at...
Should You Buy First Data Corporation (FDC) or Civ... First Data Corporation (NYSE:FDC) shares are up more than 9.10% this year and recently increased 0.33% or $0.06 to settle at $18.23. Civeo Corporation...